Pfizer Inc. Earnings Recaps
Q2 2026
Aug 6, 2026
Pfizer’s shares rose 3.1% following Q2 2026 results, driven primarily by raised revenue guidance and strong growth in acquired product portfolios, signaling investor approval of the company’s strategic execution and pipeline progress.
Key takeaways
- Raised full-year 2026 revenue guidance midpoint, while reaffirming adjusted diluted EPS guidance.
- Acquired product revenues grew 25% operationally year-over-year, excluding prior year’s one-time items.
- Legacy Seagen U.S. portfolio advanced with 21% year-over-year revenue growth, adjusting for onetime stocking.
- Pipeline progress includes 3 regulatory approvals, 6 key data readouts, and 8 pivotal study starts in first half of 2026.
- Cost savings initiatives updated with an additional $1 billion from realignment and $3 billion total expected from manufacturing optimization through 2029.
Q1 2026
May 7, 2026
Pfizer's shares were little changed, rising 0.9% after earnings as the company's quarterly results and outlook broadly met market expectations without providing a clear catalyst for a larger move.
Key takeaways
- Total revenues and adjusted diluted EPS exceeded internal expectations, supporting steady near-term financial performance.
- Launched and acquired products grew 22% operationally, with oncology (notably Seagen) achieving 20% year-over-year revenue growth.
- Nurtec contributed 41% operational growth, driven by strong demand across acute and preventive migraine treatments.
- Progress on R&D remains on track, with three positive Phase III readouts and plans for approximately 20 pivotal study starts in 2026.
- Legal developments, including Vyndamax patent settlements and a favorable Belgian court ruling on Comirnaty contracts, enhance long-term growth visibility and cash flow prospects.
Q3 2025
Nov 5, 2025
Pfizer reported strong third-quarter 2025 results, leveraging strategic partnerships and clinical advancements to enhance its competitive position in the pharmaceutical landscape.
Key takeaways
- Established a landmark agreement with the U.S. government, addressing key policy impacts and committing to U.S. manufacturing investments.
- Advanced the proposed acquisition of Metsera, with potential to enhance Pfizer’s portfolio in obesity treatments despite external competitive offers.
- Received encouraging Phase II clinical data for SSGJ-707, with plans for a robust clinical development program to unlock its potential.
- Presented breakthrough results at ESMO from multiple oncology studies, reinforcing portfolio strength and expanding addressable patient populations across various cancer types.